



February 26 2025

News Release

Company name: TMS Co., Ltd.
Name of representative: Takuro Wakabayashi, Chief Executive Officer
(Securities code: 4891; Growth Market)

TMS Co., Ltd. Entered into a Joint Research Agreement with Tokushima University

TMS Co., Ltd. (the “Company”) announces today that the Company has completed the process for entering into a Joint Research Agreement with Tokushima University (Tokushima Prefecture).

In this joint research, the Company aims to study pharmacological activities of a novel soluble Epoxide Hydrolase (sEH) inhibitor the Company recently discovered.

This event will have no impact on the Company's financial results for the fiscal year ending February 28, 2025.

About TMS Co., Ltd.

TMS Co., Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of transformative medicines for the treatment of serious diseases in areas of high unmet medical need. The Company’s pipeline consists of a family of small molecule compounds called SMTPs (*Stachybotrys Microspora* Triprenyl Phenols) derived from a fungus. TMS’ lead program, TMS-007 (JX10), has demonstrated efficacy and safety in its Phase 2a study for the treatment of acute ischemic stroke. The Company’s robust pipeline also includes programs in resistant or uncontrolled hypertension, acute kidney injury, and spinal cord injury. TMS continues to explore new pipeline products by leveraging its established partnerships with leading academic institutions in Japan, with the intention to build a bridge between academic discoveries and the global pharmaceutical market. For more information about TMS, please visit <https://www.tms-japan.co.jp/en/>

Investor and Media Contact:
ir@tms-japan.co.jp

End